Sugi Predict

Sugi Predict / Compounds / SCHEMBL554069

SCHEMBL554069

SCHEMBL554069

O=C(OCc1ccccc1)N(CCO)CCO

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR6 P51684 1/20 0.64
▸ PAX8 Q06710 1/20 0.64
▸ ALDH1A1 P00352 5/20 0.52
▸ TDP1 Q9NUW8 2/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ LMNA P02545 3/20 0.46
▸ HCAR2 Q8TDS4 1/20 0.46
▸ MAPT P10636 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ MMP2 P08253 1/20 0.43
▸ MMP9 P14780 1/20 0.43
▸ MMP12 P39900 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15841147 0.98 CCR6 (0.62) CCR6PAX8ALDH1A1TDP1L3MBTL1
SCHEMBL6264786 0.92 CCR6 (0.57) CCR6PAX8ALDH1A1TDP1L3MBTL1
SCHEMBL13661129 0.92 CCR6 (0.57) CCR6PAX8ALDH1A1TDP1L3MBTL1
SCHEMBL14823650 0.92 CCR6 (0.56) CCR6PAX8ALDH1A1TDP1L3MBTL1
SCHEMBL25449089 0.91 CCR6 (0.56) CCR6PAX8ALDH1A1TDP1L3MBTL1
SCHEMBL554131 0.90 CCR6 (0.55) CCR6PAX8ALDH1A1TDP1L3MBTL1
SCHEMBL28460823 0.90 CCR6 (0.55) CCR6PAX8ALDH1A1TDP1L3MBTL1
SCHEMBL19795745 0.89 CCR6 (0.61) CCR6PAX8ALDH1A1TDP1L3MBTL1
SCHEMBL34466243 0.89 CCR6 (0.54) CCR6PAX8ALDH1A1TDP1L3MBTL1
SCHEMBL2434218 0.88 CCR6 (0.53) CCR6PAX8ALDH1A1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109267351-B High-flame-retardant fireproof breathable fabric and preparation process thereof 南京拓丽时装有限公司 2021-01-29 — — CN claimed
EP-4577520-A1 PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF Renagade Therapeutics Management Inc. (US) 2025-07-02 — — EP disclosed
WO-2025067464-A1 HETEROARYL COMPOUND, INTERMEDIATE THEREOF, AND PREPARATION METHOD AND USE THEREFOR 杭州圣域生物医药科技有限公司 2025-04-03 — — WO disclosed
WO-2024177424-A1 NOVEL IONIZABLE LIPID AND LIPID NANOPARTICLE CONTAINING SAME 에스티팜 주식회사 2024-08-29 — — WO disclosed
WO-2024044728-A1 PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2024-02-29 — — WO disclosed
CN-110240605-B Preparation method of artemisinin dimer 中国科学院上海药物研究所 2021-12-31 — — CN disclosed
CN-109267351-B High-flame-retardant fireproof breathable fabric and preparation process thereof 南京拓丽时装有限公司 2021-01-29 — — CN disclosed
EP-2601177-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ASTRAZENECA AB (SE) 2017-10-18 — — EP disclosed
EP-2601177-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ASTRAZENECA AB (SE) 2017-10-18 — — EP disclosed
US-20160176906-A1 Chemical Compounds ASTRAZENECA AB (SE) 2016-06-23 — — US disclosed
US-6759428-B2 SUCH AS N-((1,2)-2-(((CYANO(CYCLOPROPYL)METHYL)AMINO)CARBONYL) CYCLOHEXYL)-1H-INDOLE-2-CARBOXAMIDE; CATHEPSIN K INHIBITORS ROCHE PALO ALTO LLC 2004-07-06 — — US disclosed
US-20040077646-A1 Indole nitriles ROCHE PALO ALTO LLC 2004-04-22 — — US disclosed
EP-1404678-A1 WATER-SOLUBLE PORPHYRIN DERIVATIVES FOR PHOTODYNAMIC THERAPY, THEIR USE AND MANUFACTURE CeramOptec GmbH (DE) 2004-04-07 — — EP disclosed
US-20030138432-A1 Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs DRUG INNOVATION & DESIGN, INC. 2003-07-24 — — US disclosed
US-20030088092-A1 Water-soluble porphyrin derivatives and methods of their preparation CERAMOPTEC INDUSTRIES, INC. 2003-05-08 — — US disclosed
US-20030023081-A1 Water-soluble porphyrin derivatives for photodynamic therapy, their use and manufacture CERAMOPTEC INDUSTRIES INC. 2003-01-30 — — US disclosed
US-20030004334-A1 Water-soluble porphyrin derivatives and methods of their preparation CERAMOPTEC INDUSTRIES, INC. 2003-01-02 — — US disclosed
WO-2002098882-A1 WATER-SOLUBLE PORPHYRIN DERIVATIVES FOR PHOTODYNAMIC THERAPY, THEIR USE AND MANUFACTURE CERAMOPTEC INDUSTRIES, INC. (US) 2002-12-12 — — WO disclosed
EP-1255567-A1 SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES Drug Innovation & Design, Inc. (US) 2002-11-13 — — EP disclosed
WO-2001036003-A2 SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES DRUG INNOVATION & DESIGN, INC. (US) 2001-05-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030138432-A1 Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs PAICS, ABCB1, ABCG2 CCR6 775/4885PAX8 4476/4885ALDH1A1 589/4885
US-20030023081-A1 Water-soluble porphyrin derivatives for photodynamic therapy, their use and manufacture ALK, HCK, GCK CCR6 407/4885PAX8 1611/4885ALDH1A1 2910/4885
US-20040077646-A1 Indole nitriles TPH1, IDO1, NAT1 CCR6 1942/4885PAX8 4782/4885ALDH1A1 535/4885
US-20030088092-A1 Water-soluble porphyrin derivatives and methods of their preparation HCK, ALK, DCK CCR6 485/4885PAX8 3660/4885ALDH1A1 3048/4885
US-20030004334-A1 Water-soluble porphyrin derivatives and methods of their preparation HCK, DCK, ALK CCR6 547/4885PAX8 3856/4885ALDH1A1 3431/4885
US-20160176906-A1 Chemical Compounds BCL2, BCL2L1, BAX CCR6 2806/4885PAX8 4207/4885ALDH1A1 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.